Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19

被引：17

作者：

Ogawa, Fumihiro ^{[1
]}

Oi, Yasufumi ^{[1
]}

Nakajima, Kento ^{[1
]}

Matsumura, Reo ^{[1
]}

Nakagawa, Tomoki ^{[1
]}

Miyagawa, Takao ^{[1
]}

Sakai, Kazuya ^{[1
]}

Saji, Ryo ^{[1
]}

Taniguchi, Hayato ^{[1
]}

Takahashi, Kohei ^{[1
]}

Abe, Takeru ^{[1
]}

Iwashita, Masayuki ^{[1
]}

Nishii, Mototsugu ^{[1
]}

Takeuchi, Ichiro ^{[1
]}

机构：

[1] Yokohama City Univ, Sch Med, Dept Emergency Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan

来源：

THROMBOSIS JOURNAL | 2021年 / 19卷 / 01期

关键词：

COVID-19; Syndecan-1; Endothelial injury; Glycocalyx; Severity; Classification; ENDOTHELIAL GLYCOCALYX;

D O I：

10.1186/s12959-021-00308-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Coronavirus disease 2019 (COVID-19) pneumonitis associated with severe respiratory failure is associated with high mortality. The pathogenesis of COVID-19 is associated with microembolism or microvascular endothelial injuries. Here, we report that syndecan-1 (SDC-1), a component of the endothelial glycocalyx, may be a biomarker of severity classification for COVID-19 related to endothelial injury. Methods and analysis We analyzed the data of COVID-19 patients for 1 year from February 2020 at Yokohama City University Hospital and Yokohama City University Medical Center Hospital. We selected COVID-19 patients who required admission care, including intensive care, and analyzed the classification of severe and critical COVID-19 retrospectively, using various clinical data and laboratory data with SDC-1 by ELISA. Results We analyzed clinical and laboratory data with SDC-1 in five severe COVID-19 and ten critical COVID-19 patients. In the two groups, their backgrounds were almost the same. In laboratory data, the LDH, CHE, and CRP levels showed significant differences in each group (P = 0.032, P < 0.0001, and P = 0.007, respectively) with no significant differences in coagulation-related factors (platelet, PT-INR, d-dimer, ISTH score; P = 0.200, 0.277, 0.655, and 0.36, respectively). For the clinical data, the SOFA score was significantly different from admission day to day 14 of admission (p < 0.0001). The SDC-1 levels of critical COVID-19 patients were significantly higher on admission day and all-time course compared with the levels of severe COVID-19 patients (P = 0.009 and P < 0.0001, respectively). Conclusions Temporal change of SDC-1 levels closely reflect the severity of COVID-19, therefore, SDC-1 may be a therapeutic target and a biomarker for the severity classification of Covid-19.

引用

页数：9